Corvus Pharmaceuticals, Inc. Share Price & Technical Analysis
CRVS · $12.83 (+1.74%)
Healthcare / Biotechnology
$12.83
+1.74%
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-cent…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-17% return in May, 75% avg return in past 3 year May month.
121% return in 2026, 138% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 165% | -12% | -17% | 1% | -17% | – | – | – | – | – | – | – | 121% |
| 25 | -2% | -23% | -22% | 13% | 6% | 5% | 5% | 39% | 32% | 8% | 16% | -16% | 61% |
| 24 | 18% | 10% | -18% | -17% | 47% | -18% | 44% | 67% | 20% | 63% | 2% | -41% | 177% |
| 23 | 0% | -12% | 29% | 22% | 173% | -23% | -4% | -9% | -29% | -27% | 36% | 20% | 176% |
| 22 | -28% | 0% | -11% | -19% | -23% | 0% | -10% | 11% | -11% | 13% | 0% | 0% | -78% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.31B
P/E ratio
—
52W high
$26.95
52W low
$3.49
Volume
6,82,084
Beta
0.94
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Corvus Pharmaceuticals, Inc. share price today?
- Corvus Pharmaceuticals, Inc. (CRVS) last traded around $12.83 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CRVS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CRVS. Download the app for real-time alerts.
- How can I analyze Corvus Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.